ACADIA Pharmaceuticals (Acadia) (ACAD) is one of the few healthy biotech stocks on sale. The company has fallen 8.23% YTD (year to date) and almost 26.89% from its 52-week high of $53.70. However, this is not fundamentally justified. The company’s exclusive focus on debilitating psychiatric conditions makes it far more resistant to the disruptions caused by COVID-19. The company is financially stable and would definitely not need to dilute its shares to sustain its operations. This is already a rarity in biotech space.
Acadia's stable financial condition stems from the commercial success of